AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6801218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial pressure monitoring and aggressive treatment (including mannitol therapy and drainage of cerebrospinal fluid)
Number of subjects: 127
Study 6801218 — intervention group
Group type: COMPARATOR
Intervention: Previous treatment protocol (standardized protocol without aggressive ICP treatment)
Number of subjects: 127
Study 6801218 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP greater than or equal to 25 mm Hg
Number of subjects: 127
Study 6801218 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP monitoring with aggressive treatment
Number of subjects: 127
Study 30744053 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy learning. Together. tool implemented by regular teachers in the intervention group (IG)
Number of subjects: 1144
Study 30744053 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 1144
Study 27499178 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium‐nitride‐oxide‐coated bioactive stents (BAS)
Number of subjects: 827
Study 27499178 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 827
Study 27166670 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual prostate‐specific antigen (PSA) screening for 6 years and digital rectal examination for 4 years
Number of subjects: 151
Study 27166670 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual prostate‐specific antigen (PSA) screening
Number of subjects: 151
Study 23775532 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal patch (TEP) hernioplasty
Number of subjects: 154
Study 23775532 — intervention group
Group type: COMPARATOR
Intervention: Open tension‐free plug and patch (PP) technique
Number of subjects: 154
Study 21745755 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 14
Study 21745755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19020533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (MgCl(2)) 2.5 g (equivalent to 450 mg of elemental magnesium) for 4 months
Number of subjects: 82
Study 19020533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 17894706 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cyclosporine (CyA) therapy at individualized effective doses
Number of subjects: 51
Study 17894706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cyclosporine (CyA) therapy
Number of subjects: 51
Study 17894706 — intervention group
Group type: COMPARATOR
Intervention: Both treatment schedules
Number of subjects: 51
Study 15250006 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐V Impulse System (mechanical thrombembolic prophylaxis)
Number of subjects: 104
Study 15250006 — intervention group
Group type: COMPARATOR
Intervention: Low dose heparin (control group)
Number of subjects: 104
Study 15250006 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 104
Study 12176767 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group (29 persons) - received training on earplug insertion
Number of subjects: 54
Study 12176767 — intervention group
Group type: COMPARATOR
Intervention: Untrained group (25 persons) - acted as controls
Number of subjects: 54
Study 10521819 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal cells identified using double-density gradient and MACS methods, followed by FISH technique.
Number of subjects: 66
Study 10521819 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal sex determination using identified fetal cells.
Number of subjects: 66
Study 10521819 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmation of aneuploidies found in previous prenatal diagnosis.
Number of subjects: 66
Study 7677459 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin infusion for 7 days
Number of subjects: 9
Study 7677459 — intervention group
Group type: COMPARATOR
Intervention: Control period (enteral feeding alone)
Number of subjects: 9
Study 2205609 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture-like transcutaneous electrical nerve stimulation
Number of subjects: 11
Study 2205609 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 11
Study 6994791 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 8
Study 6994791 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.6 mg)
Number of subjects: 8
Study 6994791 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined metoclopramide and atropine
Number of subjects: 8
Study 6994791 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 8
Study 31132908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet and pen version
Number of subjects: 30
Study 31132908 — intervention group
Group type: COMPARATOR
Intervention: Pen and paper version
Number of subjects: 30
Study 31132908 — intervention group
Group type: COMPARATOR
Intervention: Tablet and finger version
Number of subjects: 30
Study 27493198 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fexofenadine and ranitidine (blockade)
Number of subjects: 24
Study 27493198 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 24
Study 26187277 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese Medicine (TCM) adjunctive treatment for fractures, including Shu-jing-huo-xue-tang and Rhizoma Drynariae (Gu-sui-bu) as common prescriptions.
Number of subjects: 115327
Study 26187277 — intervention group
Group type: COMPARATOR
Intervention: Non-TCM treatment for fractures (control group).
Number of subjects: 115327
Study 22888821 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 588
Study 20537624 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone
Number of subjects: 365
Study 20537624 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone (IMP)
Number of subjects: 365
Study 20537624 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen supplementation
Number of subjects: 365
Study 19591990 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist administration initiated when the lead follicle reaches 14 mm
Number of subjects: 0
Study 19591990 — intervention group
Group type: COMPARATOR
Intervention: Control group (GnRH antagonist administration not specified)
Number of subjects: 0
Study 17224445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 23
Study 15482599 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a
Number of subjects: 0
Study 12014386 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (INDO) 0.2 mg/kg at 12 h intervals
Number of subjects: 232
Study 12014386 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (IBU) first dose 10 mg/kg followed by two doses of 5 mg/kg at 24 h intervals
Number of subjects: 232
Study 10439371 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg i.v. 10 min before chemotherapy)
Number of subjects: 225
Study 10439371 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg i.v. 10 min before chemotherapy) + Alprazolam (1 mg per os 1 hour before chemotherapy, 0.5 mg at H+6 for C1; 0.75 or 1.5 mg at H-48, H-24, H-1 for C2 and C3, 0.5 mg at H+6)
Number of subjects: 225
Study 10439371 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron plus Alprazolam
Number of subjects: 225
Study 7766738 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of 50 micrograms of octreotide
Number of subjects: 9
Study 2277579 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 3 mL normal saline into the P6 acupuncture point after anesthesia
Number of subjects: 64
Study 2277579 — intervention group
Group type: COMPARATOR
Intervention: Standard fentanyl-valium-thiopentone anesthesia alone
Number of subjects: 64
Study 7470769 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg, 50 mg, 100 mg)
Number of subjects: 8
Study 7470769 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (25 mg, 50 mg, 100 mg)
Number of subjects: 8
Study 7470769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7470769 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline and Desipramine
Number of subjects: 8
Study 29374357 — intervention group
Group type: EXPERIMENTAL
Intervention: Stigmatizing language note
Number of subjects: 413
Study 29374357 — intervention group
Group type: COMPARATOR
Intervention: Neutral language note
Number of subjects: 413
Study 27379603 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal growth groups led by experienced psychologists for 9 weeks using Yalom and Leszcz's interpersonal process model.
Number of subjects: 325
Study 24122296 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance and aerobic exercise intervention
Number of subjects: 57
Study 24122296 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study 22618963 — intervention group
Group type: EXPERIMENTAL
Intervention: Let Us Protect Our Future intervention
Number of subjects: 0
Study 20375263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (480 mL; 54% juice; 835 mg total polyphenols; 94.47 mg anthocyanins)
Number of subjects: 15
Study 18522171 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiochemotherapy using teniposide
Number of subjects: 0
Study 18522171 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study 15781835 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg of levetiracetam
Number of subjects: 24
Study 15781835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12643118 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 12643118 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 0
Study 12643118 — intervention group
Group type: COMPARATOR
Intervention: Aggressive medical therapy
Number of subjects: 0
Study 11034868 — intervention group
Group type: EXPERIMENTAL
Intervention: Side Effect and Life Satisfaction (SEALS) inventory
Number of subjects: 307
Study 11034868 — intervention group
Group type: COMPARATOR
Intervention: Profile of Mood States (POMS)
Number of subjects: 307
Study 11034868 — intervention group
Group type: COMPARATOR
Intervention: Hospital Anxiety and Depression (HAD) scale
Number of subjects: 307
Study 11034868 — intervention group
Group type: COMPARATOR
Intervention: Medical Outcomes Study‐Cognitive Functioning (MOS‐COG) scale
Number of subjects: 307
Study 9346622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ceftazidime and flucloxacillin plus oral and enteral decontamination with colistin, tobramycin, and amphotericin B (group 1)
Number of subjects: 108
Study 9346622 — intervention group
Group type: COMPARATOR
Intervention: Enteral amphotericin B alone (group 2)
Number of subjects: 108
Study 1869454 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated RT (70.4 Gy in 64 fractions of 1.1 Gy given twice a day)
Number of subjects: 112
Study 1869454 — intervention group
Group type: COMPARATOR
Intervention: Conventional RT (66 Gy in 33 fractions of 2 Gy each)
Number of subjects: 112
Study 1869454 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated RT
Number of subjects: 112
Study 1869454 — intervention group
Group type: COMPARATOR
Intervention: Conventional RT
Number of subjects: 112
Study 6415595 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolite (carbon‐coated) ventilation tubes
Number of subjects: 44
Study 6415595 — intervention group
Group type: COMPARATOR
Intervention: Conventional silicone tube
Number of subjects: 44
Study 31338732 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches for 6 weeks
Number of subjects: 22
Study 31338732 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 22
Study 29408562 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity lifestyle intervention delivered by health coaches; 16 in-person sessions and 6 telephone sessions in the first 6 months, followed by at least monthly sessions for 18 months.
Number of subjects: 803
Study 29408562 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by primary care practitioners with information on weight management and reimbursement for obesity treatment.
Number of subjects: 803
Study 29408562 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity lifestyle intervention
Number of subjects: 803
Study 27080034 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg daily on-demand
Number of subjects: 598
Study 27080034 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg daily continuously
Number of subjects: 598
Study 25265102 — intervention group
Group type: EXPERIMENTAL
Intervention: Precall
Number of subjects: 29
Study 23159552 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting or endarterectomy
Number of subjects: 2272
Study 21260942 — intervention group
Group type: EXPERIMENTAL
Intervention: Entropy monitoring
Number of subjects: 50
Study 21260942 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard monitoring)
Number of subjects: 50
Study 18058456 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Number of subjects: 355
Study 18058456 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 355
Study 18058456 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 355
Study 18058456 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 10 mg
Number of subjects: 355
Study 16102231 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual go/no-go task based on spatial, temporal, or object stimulus features
Number of subjects: 0
Study 16102231 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual go/no-go task
Number of subjects: 0
Study 12100802 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia
Number of subjects: 220
Study 12100802 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous meperidine
Number of subjects: 220
Study 10626032 — intervention group
Group type: EXPERIMENTAL
Intervention: 44 mg/24 hour nicotine patch for 4 weeks
Number of subjects: 382
Study 10626032 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 mg/24 hour nicotine patch for 6 weeks
Number of subjects: 382
Study 10626032 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (minimal, brief individual counseling, group therapy)
Number of subjects: 382
Study 7476297 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g ethanol/kg body weight
Number of subjects: 9
Study 7476297 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g ethanol/kg body weight
Number of subjects: 9
Study 7476297 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g ethanol/kg body weight)
Number of subjects: 9
Study 1493666 — intervention group
Group type: EXPERIMENTAL
Intervention: 12,000 U calcium heparin s.c. every 24 h (group 2)
Number of subjects: 80
Study 1493666 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment (group 1)
Number of subjects: 80
Study 2862370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (12 mg single oral dose)
Number of subjects: 30
Study 2862370 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC, daily for eight days, total dose 1.3 g)
Number of subjects: 30
Study 2862370 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching)
Number of subjects: 30
Study 29189517 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 90
Study 29189517 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/naloxone
Number of subjects: 90
Study 29189517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 27033026 — intervention group
Group type: EXPERIMENTAL
Intervention: omega‐3 (4 g/day) and vitamin E (400 IU/day)
Number of subjects: 60
Study 27033026 — intervention group
Group type: EXPERIMENTAL
Intervention: omega‐3 (4 g/day) and vitamin E placebo (OP)
Number of subjects: 60
Study 27033026 — intervention group
Group type: COMPARATOR
Intervention: omega‐3 and vitamin E placebos (PP)
Number of subjects: 60
Study 25471216 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (420 mg) + EPA (80 mg) supplementation
Number of subjects: 98
Study 25471216 — intervention group
Group type: COMPARATOR
Intervention: Iron (50 mg) supplementation
Number of subjects: 98
Study 25471216 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (50 mg) + DHA (420 mg) + EPA (80 mg) supplementation
Number of subjects: 98
Study 25471216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 23225089 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% polyvinylpyrrolidone and 0.1% clobetasone butyrate, 1 drop BID
Number of subjects: 40
Study 23225089 — intervention group
Group type: COMPARATOR
Intervention: 2% polyvinylpyrrolidone eyedrops and placebo
Number of subjects: 40
Study 21633832 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sTREM-1 below the limit of detection
Number of subjects: 96
Study 21633832 — intervention group
Group type: COMPARATOR
Intervention: Serum sTREM-1 above the limit of detection
Number of subjects: 96
Study 19281081 — intervention group
Group type: EXPERIMENTAL
Intervention: S-carboxymethylcysteine (carbocisteine)
Number of subjects: 0
Study 16411052 — intervention group
Group type: EXPERIMENTAL
Intervention: GP arm (intervention)
Number of subjects: 3657
Study 16411052 — intervention group
Group type: COMPARATOR
Intervention: Hospital arm (control)
Number of subjects: 3657
Study 16411052 — intervention group
Group type: EXPERIMENTAL
Intervention: GPs with more than 25 patients visited/day
Number of subjects: 3657
Study 16411052 — intervention group
Group type: EXPERIMENTAL
Intervention: GPs incorrectly recommending screening of colorectal cancer
Number of subjects: 3657
Study 12496140 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion (125 mg/kg/h for 15 min, then 25 mg/kg/h)
Number of subjects: 8
Study 12496140 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study 10857934 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 34
Study 10857934 — intervention group
Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 34
Study 9506873 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal cognitive behavioral treatment (MMCBT) for 4 weeks
Number of subjects: 469
Study 9506873 — intervention group
Group type: COMPARATOR
Intervention: Control group (ordinary treatment through general practitioners)
Number of subjects: 469
Study 7931189 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha therapy
Number of subjects: 50
Study 7931189 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 50
Study 7931189 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV DNA detection in PBMC
Number of subjects: 50
Study 7931189 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV DNA in different cell types
Number of subjects: 50
Study 7931189 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of multimers of free HBV DNA
Number of subjects: 50
Study 3290578 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy using Flutamide and LHRH agonist [D‐Trp6]LHRH ethylamide for an average of 26 months (3‐59 months)
Number of subjects: 199
Study 3290578 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy using Flutamide and LHRH agonist [D‐Trp6]LHRH ethylamide
Number of subjects: 199
Study 31734452 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified global alignment and proportion scoring with body mass index and bone mineral density (GAPB)
Number of subjects: 203
Study 31734452 — intervention group
Group type: COMPARATOR
Intervention: Global alignment and proportion (GAP) score
Number of subjects: 203
Study 31734452 — intervention group
Group type: COMPARATOR
Intervention: Scoliosis Research Society (SRS)‐Schwab classification
Number of subjects: 203
Study 31734452 — intervention group
Group type: COMPARATOR
Intervention: Age‐adjusted alignment goals
Number of subjects: 203
Study 29778106 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bromfenac 0.09% twice daily for 2 weeks
Number of subjects: 914
Study 29778106 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone 0.1% 4 times daily with tapering
Number of subjects: 914
Study 29778106 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of topical bromfenac 0.09% and dexamethasone 0.1%
Number of subjects: 914
Study 26957853 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 20
Study 24031025 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (intermittent arm ischaemia through four cycles of 5‐min inflation followed by 5‐min deflation of a blood‐pressure cuff)
Number of subjects: 333
Study 24031025 — intervention group
Group type: COMPARATOR
Intervention: Control group (primary percutaneous coronary intervention without remote ischaemic conditioning)
Number of subjects: 333
Study 24031025 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning
Number of subjects: 333
Study 21332853 — intervention group
Group type: EXPERIMENTAL
Intervention: Music delivered by earphones for 20 minutes before surgery
Number of subjects: 183
Study 21332853 — intervention group
Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 183
Study 20021707 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal norms (PN)
Number of subjects: 0
Study 20021707 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of adverse consequences
Number of subjects: 0
Study 20021707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascription of responsibility
Number of subjects: 0
Study 20021707 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived control over problems
Number of subjects: 0
Study 18691799 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual BLS refresher training (IT)
Number of subjects: 120
Study 18691799 — intervention group
Group type: COMPARATOR
Intervention: Group refresher training (GT)
Number of subjects: 120
Study 16076733 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread supplemented with prebiotics and antioxidants
Number of subjects: 38
Study 16076733 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal water genotoxicity
Number of subjects: 38